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Introduction: Lung cancer invading the spine historically has been 
considered unresectable. Nevertheless, considerable surgical prog-
ress has been made since the 1990s potentially allowing for curative 
resection. Here, we describe our surgical experience and long-term 
results.
Methods: All patients who underwent en bloc resection of non–
small-cell lung cancer invading the pulmonary sulcus and spine 
between 1991 and 2012 were retrospectively reviewed.
Results: Forty-eight patients were included. Induction therapy con-
sisted mostly of two cycles of cisplatin–etoposide and 45 Gy of 
concurrent radiation. All tumors were resected en bloc, including 
the lung, spine, and chest wall. Total vertebrectomy, hemivertebrec-
tomy, and partial vertebrectomy were required in 10 patients (21%), 
31 patients (64%), and seven patients (15%), respectively. Complete 
resection was achieved in 42 patients (88%). Postoperatively, 18 
patients (38%) stayed in the intensive care unit for a median of 15 (1–
140) days. Thirty-day and in-hospital mortality was 6%. Pathologic 
response to induction treatment was complete (n = 18) or near com-
plete (n = 6) in 24 patients (50%). After a median follow-up of 26 
(0–151) months, 24 patients are alive without recurrence. Overall 
5-year survival was 61%. Response to induction therapy (complete/
near complete versus other, p = 0.012), resection margin (R0 versus 
R1/R2, p = 0.009), and length of intensive care unit stay (p = 0.003) 
were significant prognostic factors in univariate analysis. Response 
to induction was maintained as prognostic factor in multivariable 
analysis (p = 0.048).
Conclusions: En bloc resection of the lung, chest wall, and spine for 
non–small-cell lung cancer invading the pulmonary sulcus and spine 
is feasible in experienced centers with excellent long-term outcome 
after careful patient selection. Response to induction was an indepen-
dent significant prognostic factor.
Key Words: Spine, Surgery, En bloc, Pulmonary sulcus, Non–small-
cell lung cancer.
(J Thorac Oncol. 2013;8: 1538–1544)
Non–small-cell lung cancers (NSCLCs) located along the pulmonary sulcus (or costovertebral gutter) are 
prone to invade the spine. Historically, lung cancers invading 
the spine have generally been considered unresectable and 
fatal.1 DeMeester et al.2 described the first successful cases 
of en bloc resection of lung cancer invading the spine after 
preoperative radiation. Resections were, however, limited to 
the transverse process with tangential section of the vertebral 
body. Less than a decade later, the first en bloc total verte-
brectomy in this setting was reported.3 Since then, we and 
others have published results on larger series with encourag-
ing results.4–8 Nevertheless, data on long-term outcome after 
these challenging resections remain limited. In this report, we 
describe our surgical experience and long-term results after 
multimodality treatment.
PATIENTS AND METHODS
This is a retrospective single-center study, including 
patients with pulmonary sulcus NSCLC invading the spine 
who had en bloc tumor resection. Data were retrieved from 
the electronic medical records. The study was approved by 
the institutional research ethics board at University Health 
Network. Patient informed consent was waived.
Preoperative tumor staging comprised computed tomog-
raphy (CT) of the chest and abdomen, CT or magnetic reso-
nance imaging (MRI) of the brain, bone scan, and integrated 
positron emission tomography with CT since 2005. The medi-
astinum was systematically assessed by cervical mediastinos-
copy, and patients with N2-disease were not considered for 
operation. Tumor resectability was evaluated by CT and MRI 
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of the chest and spine. Patients with tumor infiltration into the 
spinal canal or into the brachial plexus at C7 nerve root and 
above were generally considered to be inoperable.
Induction treatment consisted primarily of two cycles 
of cisplatin–etoposide concurrently with 45 Gy of radiation 
to the primary tumor. Restaging was performed with CT of 
the chest/abdomen and chest MRI. The brain was reassessed 
by CT or MRI. Patients without evidence of distant metastasis 
underwent surgical resection and are the cohort of this study. 
Surgical resection was performed in one or two stages, as 
described elsewhere.4 If a long procedure was expected (three 
or more levels of hemivertebrectomy or total vertebrectomy), 
a two-stage spinal procedure was planned. The first stage of 
tumor resection consisted of a posterior midline approach to 
the spine. The tumor was released posteriorly by a hemilami-
nectomy or complete laminectomy at the level of the tumor. 
Appropriate nerve roots were ligated off the spinal cord. 
Posterior multilevel instrumentation with pedicle screws and 
rod stabilization or pedicle screws only were performed on the 
contralateral and ipsilateral side of the tumor, respectively. The 
tumor was not exposed during this stage. In the second stage, 
the tumor was resected en bloc with the involved pulmonary 
lobe, chest wall, vertebra(e), nerve root(s), and vessel(s) with 
or without anterior spine stabilization. A posterolateral thora-
cotomy was carried out for tumors located at the level of the 
T2 vertebra or below. An anterior approach was generally per-
formed for tumors at the level of T1 and above.9 Partial verte-
bral resection typically did not require vertebral stabilization, 
whereas hemivertebrectomy required posterior vertebral sta-
bilization, and total vertebrectomy required both posterior and 
anterior vertebral stabilization.
Tumors were classified and staged according to the 7th 
edition of the Tumor, Node, Metastasis classification of malig-
nant tumors.10 A complete resection was defined as a resec-
tion with microscopic tumor-free margins (R0). Response to 
induction treatment was defined as complete, near complete, 
and partial when tumor necrosis entailed 100%, more than or 
equal to 95%, and less than 95%, respectively.
Statistical analysis was performed using IBM SPSS 19.0 
for Windows software (SPSS Inc., Chicago, IL). Univariate 
logistic regression was used to assess the impact of relevant 
variables on the incidence of major postoperative complica-
tions requiring surgery. Overall survival was estimated from 
the date of spine resection using the Kaplan–Meier survival 
analysis method. Survival differences were compared by the 
Cox regression for continuous and log-rank test or Breslow 
test when necessary for discrete variables. Significant param-
eters were further analyzed by multivariable Cox regression. A 
p value of less than or equal to 0.05 was considered significant.
RESULTS
Forty-eight consecutive patients including 31 men (65%) 
with a median age of 62 (from 32 to 78) years underwent en 
bloc resection of NSCLC invading the pulmonary sulcus from 
December 1991 to May 2012. Tumor histology was squamous 
cell carcinoma in 19 patients (40%), adenocarcinoma in 16 
patients (33%), large-cell carcinoma in three patients (6%), and 
undetermined or other NSCLC histology in 10 patients (21%). 
Clinical stages were IIB (T3N0) in three patients (6%), IIIA 
(T4N0) in 44 patients (92%), and IIIB (T4N2) in one patient 
(2%). Forty-seven patients (98%) had induction treatment con-
sisting of chemoradiation for 45 patients (94%), chemotherapy 
alone in one patient (2%), and radiation alone in one patient 
(2%). Chemotherapy consisted mostly in two cycles of cispl-
atin–etoposide. Radiation was delivered concurrently, with a 
dose of 45 Gy in 35 patients (ranged from 24 to 66 Gy).
Twenty-three patients (48%) had a two-stage procedure. 
Two patients underwent preoperative aortic endoprosthesis 
insertion for aortic wall involvement by the tumor on preop-
erative investigations (Collaud S, Waddell TK, Yasufuku K, 
et al. Thoracic aortic endografting facilitates the resection of 
tumors infiltrating the aorta). All tumors were resected en bloc. 
Complete resection (R0) was achieved in 42 patients (88%). 
Incomplete resection occurred in six patients at the level of the 
brachial plexus (n = 2), the spinal dura (n = 2), chest wall (n 
= 1), and vertebral body (n = 1). Resection of the T1 vertebra 
or above was performed in 23 patients (48%). Table 1 summa-
rizes the characteristics of the surgical specimen. Chest wall 
reconstruction was performed in 18 patients: Marlex mesh in 
nine patients, Gore-Tex mesh in seven patients, Prolene mesh 
in one patient, and myocutaneous flap in one patient.
In the postoperative period, 18 patients (38%) spent 
a median of 15 days (range, 1–140 days) in the intensive 
care unit (ICU). Complications requiring at least one sur-
gical procedure occurred in 10 patients (21%). Revisions 
occurred for dislocation of spinal instrumentation (n = 2) 
TABLE 1.  Characteristics of the Surgical Specimen
Variables n (%)
Type of lung resection
  Lobectomy 46 (96)
  Wedge resection 2 (4)
Type of vertebral resection (required stabilization)
  Total (posterior, anterior) 10 (20)
  Hemi (posterior) 31 (65)
  Partial (none) 7 (15)
No. of vertebral level resected
  One 1 (2)
  Two 4 (8)
  Three 30 (63)
  Four 12 (25)
  Five 1 (2)
No. of ribs resected
  One 1 (2)
  Two 4 (8)
  Three 12 (25)
  Four 24 (50)
  Five 7 (15)
Type of arterial resection
  None 39 (81)
  Subclavian artery 6 (13)
  Vertebral artery 1 (2)
  Aortic wall 2 (4)
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and cerebrospinal fluid leak due to a dural tear (n = 2). 
Other surgical procedures included ligation of the thoracic 
duct for chylothorax (n = 1), pulmopexy for left main bron-
chus kinking (n = 1), thyroplasty for laryngeal nerve palsy 
(n = 1), bowel resection for ischemia (n = 1), completion 
pneumonectomy for bronchoarterial fistula (n = 1), and 
debridement for wound breakdown (n = 1). Results of the 
univariate logistic regression did not demonstrate any pre-
dictive factors for the occurrence of postoperative compli-
cations requiring repeat surgery. The variables tested were 
patient’s age, period of surgery, number of resected verte-
bra/nerve roots/ribs, number of operation stages, presence 
of a thoracic inlet tumor or an arterial resection, extent of 
vertebral resection, and tumor size.
Three patients (6%) died during their hospital stay or 
within 30 days after operation: two patients from pneumonia with 
respiratory failure and one patient from a septic shock after intes-
tinal anastomotic leak following bowel resection for ischemia.
Pathologic response to induction treatment was com-
plete, near complete, and partial in 18 patients (38%), six 
patients (13%), 23 patients (49%), respectively. Median tumor 
diameter shrunk between 61 mm (range, 12–110 mm) before 
and 43 mm (range, 14–99 mm) after induction. Stages were 
ypT0N0 (n = 18), ypT3N0 (n = 8), ypT4N0 (n = 16), ypT3N1 
(n = 2), ypT4N1 (n = 2), ypT4N2 (n = 1), and ypT4N3 (n = 1).
After a median follow-up of 26 (0–151) months, 24 patients 
(50%) are alive without recurrence. Six patients had local recur-
rence within the thorax or supraclavicular lymph nodes, and 
eight patients had distant metastasis to the bone, brain, or adre-
nal gland. Seven patients were dead: four from a cause unrelated 
to cancer and three from an undetermined origin. Nevertheless, 
none of them had evidence of recurrence at last follow-up.
The 3-year and 5-year overall survivals reached 69% 
(SE = 0.07) and 61% (SE = 0.08), respectively (Figure 1). 
Table 2 summarizes the factors impacting long-term survival 
according to the results of the Cox regression and log-rank/
Breslow tests and the multivariable Cox regression. Length 
of ICU stay (p = 0.003), pathologic response rate to induction 
therapy (p = 0.012), and R0 resection (p = 0.009) were signifi-
cant predictors of survivals in a univariate analysis, while only 
the pathologic response rate to induction therapy remained 
significant in the multivariable analysis (p = 0.048). Survival 
curves according to pathologic response and completeness of 
resection are depicted in Figures 2 and 3. The survival of the 
last 24 patients operated on in this study showed a tendency 
toward better survival compared with the first 24 patients 
(p = 0.062, Figure 4). Table 3 shows the distribution of the dif-
ferent survival predictors between these two groups.
DISCUSSION
Although once considered incurable, carefully selected 
patients with NSCLC invading the spine can currently 
FIGURE 1.  Overall long-term survival.
TABLE 2.  Identification of Survival Predictors
Variables n
Univariate Multivariate
p HR 95% CI p HR 95% CI
Age 48 0.246
Sex (female vs. male) 17 vs. 31 0.791
Histology (ad vs. sq vs. lc vs. un. vs. other) 16 vs. 19 vs. 3 vs. 8 vs. 2 0.639
pStage (0 vs. II vs. III) 18 vs. 8 vs. 22 0.284
ypN stage (ypN0 vs. ypN+) 42 vs. 6 0.928
ypT stage (ypT0 vs. ypT3-4) 18 vs. 30 0.136
Response to induction (pCR/pNR vs. pPR) 24 vs. 23 0.012 0.227 0.071–0.724 0.048 0.285 0.083–0.987
Residual margin (R0 vs. R1/R2) 42 vs. 6 0.009 0.196 0.057–0.666 0.482 0.577 0.125–2.672
Period of surgery (patients 1–24 vs. 25–48) 24 vs. 24 0.062
ICU length of stay 48 0.003 1.018 1.006–1.031 0.116 1.011 0.997–1.026
Bold values indicate statistical significance.
HR, hazard ratio; CI, confidence interval; ad, adenocarcinoma; sq, squamous cell carcinoma; lc, large-cell carcinoma; un., undetermined; pCR, pathologic complete response; pNR, 
pathologic near complete response; pPR, pathologic partial response; ICU, intensive care unit.
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potentially be resected for cure. A 5-year survival rate of 61% 
in patients who would historically have received palliative 
chemoradiotherapy and who generally died a morbid and pain-
ful death is a remarkable advancement in the field. However, 
multimodality treatment, very careful patient selection, and 
complete surgical resection are mandatory prerequisites.
There is no prospective randomized control study exam-
ining neoadjuvant versus adjuvant treatment in the setting of 
pulmonary sulcus NSCLC invading the spine. Therefore, 
the optimal treatment strategy relies on data derived from 
retrospective and prospective case series. Initial and long-
term results of the Southwest Oncology Group Trial 9416 
FIGURE 2.  Survivals according 
to pathologic response rate to 
induction.
FIGURE 3.  Survivals according to 
the surgical resection margins.
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(Intergroup Trial 0160) were reported in 2001 and 2007.11,12 
In this series, patients with mediastinoscopy-negative T3-4 
N0-1 superior pulmonary sulcus NSCLC received two cycles 
of cisplatin and etoposide concurrently with 45 Gy of radia-
tion, followed by surgical resection and two additional cycles 
of adjuvant chemotherapy. This treatment modality was asso-
ciated with markedly improved local control and overall sur-
vival compared with previous studies of radiation followed by 
resection. Thus, this treatment strategy became the standard 
of care for NSCLC of the pulmonary sulcus in many centers 
including ours.4,13 Nevertheless, the presence of vertebral 
resection impacts substantially on postoperative recovery and 
can consequently jeopardizes the administration of postopera-
tive chemotherapy.
Induction chemoradiotherapy can facilitate resection 
of the primary tumor and potentially inhibit the development 
of distant metastasis.4 Our results after two cycles of cispla-
tin and etoposide with concurrent 45 Gy of radiation have 
been very encouraging. In fact, the median tumor diameter 
shrunk 18 mm after treatment. Complete surgical resections 
with free margins were achieved in 88% of the patients. The 
rates of complete resection vary in the literature from 79% to 
83% and up to 100% in a smaller study for en bloc resections 
(Table 4).4,7,8 When taking into account reports of “non–en 
bloc” resections, also described as “intralesional” resections, 
results for “complete resections” were reported between 
56% and 65% for superior pulmonary sulcus tumors.14,15 In 
our study, the completeness of surgical resection was a sta-
tistically significant predictor for survival (p = 0.009). At 
5 years, patients with an R0 resection have a 69% survival 
(SE = 0.086) compared with 0% when the resection was 
incomplete. Underscoring the importance of preoperative 
imaging and meticulous surgical evaluation to strive to oper-
ate only on patients where R0 resection seems technically 
feasible with a reasonable certainty. Induction chemoradia-
tion provides better pathologic response than induction che-
motherapy alone. Patients in our cohort achieved a complete 
pathologic response (ypT0N0) in 38%, confirming our earlier 
experience of 43%.4 Survival analysis revealed that pathologic 
response rate was as a statistically significant predicting factor 
FIGURE 4.  Survivals according to the study period.
TABLE 3.  Distribution of Survival Predictors between the 
First and Last 24 Patients
Variables Patients 1–24, n Patients 25–48, n pa
pCR or pNR 14 10 0.387
R0 20 22 0.666
No ICU stay 10 8 0.766
aFrom Fisher’s exact test (bilateral).
pCR, pathologic complete response; pNR, pathologic near complete response; ICU, 
intensive care unit.
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for survival (p = 0.012). Indeed, patients with a complete or 
near complete response had a 5-year survival of 79.6% (SE = 
0.094) compared with 35.1% (SE = 0.139) if the response 
was partial. These findings remained true when patients with 
incomplete surgical resection were excluded from the analysis 
(data not shown, p = 0.038).
Neoadjuvant treatment and in particular chemoradio-
therapy is thought to increase the risk of postoperative com-
plications and death.16 This could be somehow confirmed in 
the setting of pulmonary sulcus NSCLC invading the spine 
(Table 4). Mortality rates after en bloc resection ranged from 
0% to 17% in the literature.4,6–8,17 The three groups showing no 
mortality administered induction therapy in a minority of their 
patients, ranging from 30% to 58% and neoadjuvant treatment 
consisted mainly of chemotherapy without radiation.6,8,17 In 
comparison mortality reached 6% in our series, where most of 
the patients received neoadjuvant chemoradiation. In a smaller 
series, one in-hospital death was noted (17% mortality) after 
induction consisting in two cycles of a carboplatin-based dou-
blet with concurrent radiation (50 Gy).7 There is a controversy 
as to whether pneumonectomy (and especially right-sided) 
should be performed after induction therapy due to its poten-
tially associated high morbidity/mortality. In one multicenter 
study of patients with IIIA-N2 disease, perioperative mortal-
ity for pneumonectomy following induction treatment was 
reported up to 26%.18 Pneumonectomy was therefore strongly 
discouraged by those investigators advocating for definitive 
chemoradiation. Nevertheless, other studies including results 
from a large series of 176 pneumonectomies for stage III dis-
ease revived the debate, as it has been demonstrated that a 
perioperative mortality rate for pneumonectomy after induc-
tion chemoradiotherapy of 3% can be achieved in experienced 
centers and after adequate patient selection.19,20 To note, none 
of these patients had spinal involvement by the tumor. In our 
current series, pneumonectomy was avoided in all patients. 
Others performed pneumonectomy in up to 16% of patients 
without perioperative mortality and following heterogeneous 
induction regimens (Table 4).6–8,17 Morbidity rates for en bloc 
resection of pulmonary sulcus tumors invading the spine 
reflect the procedure’s complexity. The morbidity for these 
procedures in experienced centers is high and varies from 
33% to 55%, depending on the definitions (Table 4).4,6–8,17
In the highly selected patient cohort of this study, the 
3-year and 5-year overall survivals reached 69% and 61%, 
respectively. These excellent results are probably related to 
careful patient selection for surgery with the aid of an accu-
rate preoperative staging and imaging. We performed cervical 
mediastinoscopy to rule out mediastinal lymph node disease 
in all our patients given the poor prognosis of patients with 
T4N2-N3 tumors.2,21 Interestingly, when dividing our expe-
rience into the early (first 24 patients) and late periods (last 
24 patients), there was a trend in survival improvement for 
patients treated in the second period (p = 0.062). We specu-
late that the reason for this difference is multifactorial and 
includes among other factors, better patient selection with 
the introduction of positron emission tomography with CT 
for staging in 2005 and the refinement of surgical technique 
with experience and the introduction of the staged procedure. 
It is our impression that the staged procedure, with a 1-week 
recovery and physiotherapy period between the two stages, is 
better tolerated by the patients in general with less pulmonary 
complications. However, it is important to note that there was 
no difference in the distribution of the three prognostic fac-
tors—complete/near complete pathologic response, complete 
resection, and ICU stay—between the early and late cohort of 
patients (Table 3).
Despite our positive findings, we acknowledge some 
weaknesses in this study. Patient population was highly 
selected and was operated on in an experienced high-volume 
thoracic surgery center. Therefore, these results may not reflect 
the general outcome after spine resection for pulmonary sul-
cus lung cancer. In addition, this research has a limited sample 
size and entails bias, related to its retrospective nature.
To conclude, induction with cisplatin–etoposide and 
concurrent 45 Gy radiation followed by en bloc resection of 
pulmonary sulcus NSCLC invading the spine led to high rates 
of pathologic complete response and allows complete surgi-
cal resection in 88% of patients in experienced centers and 
after careful patient selection. Despite this aggressive treat-
ment and its substantial morbidity/mortality, excellent long-
term survival can be achieved. Future studies should focus 
on optimal systemic treatment to reduce the rate of distant 
recurrences. Efforts should be directed at strategies to more 
accurately image these patients in an attempt to reduce the 
TABLE 4.  Summary of Relevant Variables among Different Induction Treatment Regimen
Author n Induction Treatment Pneumonectomy (%) Morbidity (%) Mortality (%) 5-Year Survival (%)
Grunenwald et al.8 19 26% chemotherapy 16 53 0 14
11% radiation
21% chemoradiation
Yokomise et al.7 6 100% chemoradiation 0 33 17 67
Fadel et al.17 54 44% chemotherapy 2 55 0 31
6% chemoradiation
Schirren et al.6 20 30% chemotherapy 5 40 0 47
Present study 48 2% chemotherapy 0 21a 6 61
2% radiation
94% chemoradiation
aRequiring operation.
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rate of incomplete resections which do not provide any benefit 
to the patients. Further improvement of surgical techniques 
should aim to minimize postoperative morbidity, potentially 
enabling more patients to be resected for cure with less peri-
operative morbidity. It is important to note that with advances 
in the delivery of chemotherapy, radiation, and surgical care, 
patients once thought to be unresectable can be offered multi-
modality treatment and potentially curative resection.
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